Journal
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
Volume 83, Issue 4, Pages 791-800Publisher
WILEY
DOI: 10.1111/bcp.13164
Keywords
infant; neonate; oxycodone; pharmacokinetics; preterm
Categories
Ask authors/readers for more resources
AimsThis study aimed to characterize the pharmacokinetics of oxycodone and its major metabolites in infants and covered the age range between extremely preterm neonates and 2-year-old infants. MethodsSeventy-nine infants (gestational age 23-42 weeks; postnatal age 0-650 days) received intravenous oxycodone hydrochloride trihydrate at a dose of 0.1mgkg(-1) during or after surgery. Three to seven blood samples were taken from each infant, and plasma concentrations of oxycodone, noroxycodone, oxymorphone, and noroxymorphone were quantified. The unconjugated forms of these compounds were determined in urine collected after up to 24 or 48h from 25 infants. Pharmacokinetics was determined using noncompartmental analysis and reported for six clinically relevant age groups based on postmenstrual age. ResultsOxycodone pharmacokinetics changed markedly with patient age. Preterm neonates were found to have the highest pharmacokinetic variability out of the study population. In extremely preterm neonates (n=6) median of elimination half-life was 8.8h (range 6.8-12.5), in preterm (n=11) 7.4h (4.2-11.6), and in older neonates (n=22) 4.1h (2.4-5.8), all of which were significantly longer than that in infants aged 6-24 months (n=12) 2.0h (1.7-2.6). Median renal clearance was fairly constant in all age groups, whereas non-renal clearance markedly increased with age. Noroxycodone was the major metabolite in plasma and urine. ConclusionsOxycodone elimination is slower and pharmacokinetic variability more pronounced in neonates when compared to older infants. These findings highlight the importance of careful dose titration for neonates.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available